Accepted for Publication: October 27, 2021.
Published Online: April 21, 2022. doi:10.1001/jamaoncol.2022.0168
Corresponding Authors: Hanneke W. M. van Laarhoven, MD, PhD, Department of Medical Oncology, Cancer Center, Amsterdam UMC, University of Amsterdam, Amsterdam Meibergdreef 9, Room D3-221.1, Amsterdam 1105 AZ, The Netherlands (h.vanlaarhoven@amsterdamumc.nl).
Author Contributions: Prof van Laarhoven had full access to all of the data in the study and takes responsibility for the integrity of the data and the accuracy of the data analysis. Profs Besselink, Wilmink, and van Laarhoven contributed equally as last authors.
Concept and design: Pijnappel, Suurmeijer, Groot Koerkamp, Ghaneh, van Eijck, Büchler, Wilmink, van Laarhoven.
Acquisition, analysis, or interpretation of data: Pijnappel, Suurmeijer, Kos, Siveke, Salvia, Ghaneh, van Etten-Jamaludin, Abrams, Brasiuniene, Casadei, Van Laethem, Berlin, Boku, Conroy, Golcher, Sinn, Neoptolemos, van Tienhoven, Besselink, Wilmink, van Laarhoven.
Drafting of the manuscript: Pijnappel, Kos, van Etten-Jamaludin, van Laarhoven.
Critical revision of the manuscript for important intellectual content: Pijnappel, Suurmeijer, Groot Koerkamp, Kos, Siveke, Salvia, Ghaneh, van Eijck, Abrams, Brasiuniene, Büchler, Casadei, Van Laethem, Berlin, Boku, Conroy, Golcher, Sinn, Neoptolemos, van Tienhoven, Besselink, Wilmink, van Laarhoven.
Statistical analysis: Pijnappel, Kos.
Administrative, technical, or material support: Suurmeijer, Conroy, Sinn, Besselink.
Supervision: Groot Koerkamp, Salvia, Ghaneh, van Eijck, Büchler, Casadei, Boku, Wilmink, van Laarhoven.
Other—Expert in the Delphi consensus writing, review, and editing: Conroy.
Conflict of Interest Disclosures: Prof Siveke reported grants from Bristol Myers Squibb, Celgene, Roche, Immunocore, Novartis, Shire, Bayer, Baxalta, AstraZeneca, and Servier; equity in itheranostics and Pharma15; and serving as a board member for Pharma15, all outside the submitted work. Dr Brasiūnienė reported personal fees for speaking engagements, consulting, and travel expenses from Roche, Eli Lilly, Ipsen, and Servier, all outside the submitted work. Dr Berlin reported personal fees from Ipsen, Bayer, Mirati, Clovis, Seagen, QED Therapeutics, and EMD Serono; grants for clinical trials from EMD Serono, Bristol Myers Squibb, Novartis, Immunomedics, Dragonfly, Boston Biomedical, Symphogen, I-Mab, Karyopharm, Pfizer, and Astellas; and personal fees from Novocure, Karyopharm, and Pancreatic Cancer Action Network, all outside the submitted work. Dr Boku reported grants from Ono and Takeda and personal fees from Taiho, Ono, and Bristol Myers Squibb, all outside the submitted work. Dr Sinn reported personal fees from Amgen, AstraZeneca, Sanofi, Servier, Merck Sharp & Dohme, Bristol Myers Squibb, Incyte, Pfizer, and Pierre Fabre outside the submitted work. Prof Neoptolemos reported grants from Heidelberger Stiftung Chirurgie, Dietmar Hopp Stiftung, and Stiftung Deutsche Krebshilfe outside the submitted work. Dr Wilmink reported grants from Novartis and Servier and nonfinancial support from Merck, Nordic, Celgene, and Servier, all outside the submitted work. Prof van Laarhoven reported grants, personal fees, and/or nonfinancial support from Bristol Myers Squibb, Bayer, Eli Lilly, Dragonfly, Celgene, Janssen, Incyte, Merck, Nordic Pharma, Roche, Servier; and grants from Philips, all outside the submitted work. No other disclosures were reported.
1.Carrato
A , Falcone
A , Ducreux
M ,
et al. A systematic review of the burden of pancreatic cancer in Europe: real-world impact on survival, quality of life and costs.
J Gastrointest Cancer. 2015;46(3):201-211. doi:
10.1007/s12029-015-9724-1
PubMedGoogle ScholarCrossref 2.McGuigan
A , Kelly
P , Turkington
RC , Jones
C , Coleman
HG , McCain
RS . Pancreatic cancer: a review of clinical diagnosis, epidemiology, treatment and outcomes.
World J Gastroenterol. 2018;24(43):4846-4861. doi:
10.3748/wjg.v24.i43.4846
PubMedGoogle ScholarCrossref 5.Clark
GM , Zborowski
DM , Culbertson
JL ,
et al. Clinical utility of epidermal growth factor receptor expression for selecting patients with advanced non-small cell lung cancer for treatment with erlotinib.
J Thorac Oncol. 2006;1(8):837-846. doi:
10.1016/S1556-0864(15)30414-7
PubMedGoogle ScholarCrossref 10.Pijnappel
EN , Suurmeijer
JA , Groot Koerkamp
B ,
et al. Mandatory reporting measurements in trials for potentially resectable pancreatic cancer. In: Søreide
K , Stättner
S , eds.
Textbook of Pancreatic Cancer: Principles and Practice of Surgical Oncology. Springer; 2021:107-118. doi:
10.1007/978-3-030-53786-9_8 13.Abrams
RA , Winter
KA , Regine
WF ,
et al. Failure to adhere to protocol specified radiation therapy guidelines was associated with decreased survival in RTOG 9704—a phase III trial of adjuvant chemotherapy and chemoradiotherapy for patients with resected adenocarcinoma of the pancreas.
Int J Radiat Oncol Biol Phys. 2012;82(2):809-816. doi:
10.1016/j.ijrobp.2010.11.039
PubMedGoogle ScholarCrossref 14.Caprotti
R , Brivio
F , Fumagalli
L ,
et al. Free-from-progression period and overall short preoperative immunotherapy with IL-2 increases the survival of pancreatic cancer patients treated with macroscopically radical surgery.
Anticancer Res. 2008;28(3B):1951-1954.
PubMedGoogle Scholar 15.Casadei
R , Di Marco
M , Ricci
C ,
et al. Neoadjuvant chemoradiotherapy and surgery versus surgery alone in resectable pancreatic cancer: a single-center prospective, randomized, controlled trial which failed to achieve accrual targets.
J Gastrointest Surg. 2015;19(10):1802-1812. doi:
10.1007/s11605-015-2890-4
PubMedGoogle ScholarCrossref 16.Conroy
T , Hammel
P , Hebbar
M ,
et al; Canadian Cancer Trials Group, Unicancer-GI–PRODIGE Group. Folfirinox or gemcitabine as adjuvant therapy for pancreatic cancer.
N Engl J Med. 2018;379(25):2395-2406. doi:
10.1056/NEJMoa1809775
PubMedGoogle ScholarCrossref 17.Farnell
MB , Pearson
RK , Sarr
MG ,
et al; Pancreas Cancer Working Group. A prospective randomized trial comparing standard pancreatoduodenectomy with pancreatoduodenectomy with extended lymphadenectomy in resectable pancreatic head adenocarcinoma.
Surgery. 2005;138(4):618-628. doi:
10.1016/j.surg.2005.06.044
PubMedGoogle ScholarCrossref 19.Golcher
H , Brunner
TB , Witzigmann
H ,
et al. Neoadjuvant chemoradiation therapy with gemcitabine/cisplatin and surgery versus immediate surgery in resectable pancreatic cancer: results of the first prospective randomized phase II trial.
Strahlenther Onkol. 2015;191(1):7-16. doi:
10.1007/s00066-014-0737-7
PubMedGoogle ScholarCrossref 20.Hagiwara
Y , Ohashi
Y , Uesaka
K ,
et al; JASPAC 01 Study Group. Health-related quality of life of adjuvant chemotherapy with S-1 versus gemcitabine for resected pancreatic cancer: results from a randomised phase III trial (JASPAC 01).
Eur J Cancer. 2018;93:79-88. doi:
10.1016/j.ejca.2018.01.081
PubMedGoogle ScholarCrossref 21.Ignjatovic
I , Knezevic
S , Knezevic
D ,
et al. Standard versus extended lymphadenectomy in radical surgical treatment for pancreatic head carcinoma.
J BUON. 2017;22(1):232-238.
PubMedGoogle Scholar 22.Jang
JY , Han
Y , Lee
H ,
et al. Oncological benefits of neoadjuvant chemoradiation with gemcitabine versus upfront surgery in patients with borderline resectable pancreatic cancer: a prospective, randomized, open-label, multicenter phase 2/3 trial.
Ann Surg. 2018;268(2):215-222. doi:
10.1097/SLA.0000000000002705
PubMedGoogle ScholarCrossref 23.Jang
JY , Kang
JS , Han
Y ,
et al. Long-term outcomes and recurrence patterns of standard versus extended pancreatectomy for pancreatic head cancer: a multicenter prospective randomized controlled study.
J Hepatobiliary Pancreat Sci. 2017;24(7):426-433. doi:
10.1002/jhbp.465
PubMedGoogle ScholarCrossref 24.Jang
JY , Kang
MJ , Heo
JS ,
et al. A prospective randomized controlled study comparing outcomes of standard resection and extended resection, including dissection of the nerve plexus and various lymph nodes, in patients with pancreatic head cancer.
Ann Surg. 2014;259(4):656-664. doi:
10.1097/SLA.0000000000000384
PubMedGoogle ScholarCrossref 25.Lygidakis
NJ , Sgourakis
G , Georgia
D , Vlachos
L , Raptis
S . Regional targeting chemoimmunotherapy in patients undergoing pancreatic resection in an advanced stage of their disease: a prospective randomized study.
Ann Surg. 2002;236(6):806-813. doi:
10.1097/00000658-200212000-00013
PubMedGoogle ScholarCrossref 26.Neoptolemos
JP , Palmer
DH , Ghaneh
P ,
et al; European Study Group for Pancreatic Cancer. Comparison of adjuvant gemcitabine and capecitabine with gemcitabine monotherapy in patients with resected pancreatic cancer (ESPAC-4): a multicentre, open-label, randomised, phase 3 trial.
Lancet. 2017;389(10073):1011-1024. doi:
10.1016/S0140-6736(16)32409-6
PubMedGoogle ScholarCrossref 27.Neoptolemos
JP , Stocken
DD , Bassi
C ,
et al; European Study Group for Pancreatic Cancer. Adjuvant chemotherapy with fluorouracil plus folinic acid vs gemcitabine following pancreatic cancer resection: a randomized controlled trial.
JAMA. 2010;304(10):1073-1081. doi:
10.1001/jama.2010.1275
PubMedGoogle ScholarCrossref 28.Nimura
Y , Nagino
M , Takao
S ,
et al. Standard versus extended lymphadenectomy in radical pancreatoduodenectomy for ductal adenocarcinoma of the head of the pancreas: long-term results of a Japanese multicenter randomized controlled trial.
J Hepatobiliary Pancreat Sci. 2012;19(3):230-241. doi:
10.1007/s00534-011-0466-6
PubMedGoogle ScholarCrossref 29.Oettle
H , Neuhaus
P , Hochhaus
A ,
et al. Adjuvant chemotherapy with gemcitabine and long-term outcomes among patients with resected pancreatic cancer: the CONKO-001 randomized trial.
JAMA. 2013;310(14):1473-1481. doi:
10.1001/jama.2013.279201
PubMedGoogle ScholarCrossref 30.Oettle
H , Post
S , Neuhaus
P ,
et al. Adjuvant chemotherapy with gemcitabine vs observation in patients undergoing curative-intent resection of pancreatic cancer: a randomized controlled trial.
JAMA. 2007;297(3):267-277. doi:
10.1001/jama.297.3.267
PubMedGoogle ScholarCrossref 31.Berlin
JD , Feng
Y , Catalano
P ,
et al. An intergroup randomized phase ii study of bevacizumab or cetuximab in combination with gemcitabine and in combination with chemoradiation in patients with resected pancreatic carcinoma: a trial of the ECOG-ACRIN Cancer Research Group (E2204).
Oncology. 2018;94(1):39-46. doi:
10.1159/000480295
PubMedGoogle ScholarCrossref 32.Regine
WF , Winter
KA , Abrams
R ,
et al. Fluorouracil-based chemoradiation with either gemcitabine or fluorouracil chemotherapy after resection of pancreatic adenocarcinoma: 5-year analysis of the U.S. Intergroup/RTOG 9704 phase III trial.
Ann Surg Oncol. 2011;18(5):1319-1326. doi:
10.1245/s10434-011-1630-6
PubMedGoogle ScholarCrossref 33.Regine
WF , Winter
KA , Abrams
RA ,
et al. Fluorouracil vs gemcitabine chemotherapy before and after fluorouracil-based chemoradiation following resection of pancreatic adenocarcinoma: a randomized controlled trial.
JAMA. 2008;299(9):1019-1026. doi:
10.1001/jama.299.9.1019
PubMedGoogle ScholarCrossref 34.Reni
M , Balzano
G , Aprile
G ,
et al. Adjuvant PEFG (cisplatin, epirubicin, 5-fluorouracil, gemcitabine) or gemcitabine followed by chemoradiation in pancreatic cancer: a randomized phase II trial.
Ann Surg Oncol. 2012;19(7):2256-2263. doi:
10.1245/s10434-011-2205-2
PubMedGoogle ScholarCrossref 35.Reni
M , Balzano
G , Zanon
S ,
et al. Safety and efficacy of preoperative or postoperative chemotherapy for resectable pancreatic adenocarcinoma (PACT-15): a randomised, open-label, phase 2-3 trial.
Lancet Gastroenterol Hepatol. 2018;3(6):413-423. doi:
10.1016/S2468-1253(18)30081-5
PubMedGoogle ScholarCrossref 36.Schmidt
J , Abel
U , Debus
J ,
et al. Open-label, multicenter, randomized phase III trial of adjuvant chemoradiation plus interferon Alfa-2b versus fluorouracil and folinic acid for patients with resected pancreatic adenocarcinoma.
J Clin Oncol. 2012;30(33):4077-4083. doi:
10.1200/JCO.2011.38.2960
PubMedGoogle ScholarCrossref 37.Shimoda
M , Kubota
K , Shimizu
T , Katoh
M . Randomized clinical trial of adjuvant chemotherapy with S-1 versus gemcitabine after pancreatic cancer resection.
Br J Surg. 2015;102(7):746-754. doi:
10.1002/bjs.9775
PubMedGoogle ScholarCrossref 38.Sinn
M , Bahra
M , Liersch
T ,
et al. CONKO-005: adjuvant chemotherapy with gemcitabine plus erlotinib versus gemcitabine alone in patients after R0 resection of pancreatic cancer: a multicenter randomized phase III trial.
J Clin Oncol. 2017;35(29):3330-3337. doi:
10.1200/JCO.2017.72.6463
PubMedGoogle ScholarCrossref 39.Ueno
H , Kosuge
T , Matsuyama
Y ,
et al. A randomised phase III trial comparing gemcitabine with surgery-only in patients with resected pancreatic cancer: Japanese study group of adjuvant therapy for pancreatic cancer.
Br J Cancer. 2009;101(6):908-915. doi:
10.1038/sj.bjc.6605256
PubMedGoogle ScholarCrossref 40.Uesaka
K , Boku
N , Fukutomi
A ,
et al; JASPAC 01 Study Group. Adjuvant chemotherapy of S-1 versus gemcitabine for resected pancreatic cancer: a phase 3, open-label, randomised, non-inferiority trial (JASPAC 01).
Lancet. 2016;388(10041):248-257. doi:
10.1016/S0140-6736(16)30583-9
PubMedGoogle ScholarCrossref 41.Van Laethem
JL , Hammel
P , Mornex
F ,
et al. Adjuvant gemcitabine alone versus gemcitabine-based chemoradiotherapy after curative resection for pancreatic cancer: a randomized EORTC-40013-22012/FFCD-9203/GERCOR phase II study.
J Clin Oncol. 2010;28(29):4450-4456. doi:
10.1200/JCO.2010.30.3446
PubMedGoogle ScholarCrossref 42.Yoshitomi
H , Togawa
A , Kimura
F ,
et al; Pancreatic Cancer Chemotherapy Program of the Chiba University Department of General Surgery Affiliated Hospital Group. A randomized phase II trial of adjuvant chemotherapy with uracil/tegafur and gemcitabine versus gemcitabine alone in patients with resected pancreatic cancer.
Cancer. 2008;113(9):2448-2456. doi:
10.1002/cncr.23863
PubMedGoogle ScholarCrossref 45.Jin
C , Yao
L , Long
J ,
et al. Effect of multiple-phase regional intra-arterial infusion chemotherapy on patients with resectable pancreatic head adenocarcinoma.
Chin Med J (Engl). 2009;122(3):284-290.
PubMedGoogle Scholar 46.Kosuge
T , Kiuchi
T , Mukai
K , Kakizoe
T ; Japanese Study Group of Adjuvant Therapy for Pancreatic Cancer (JSAP). A multicenter randomized controlled trial to evaluate the effect of adjuvant cisplatin and 5-fluorouracil therapy after curative resection in cases of pancreatic cancer.
Jpn J Clin Oncol. 2006;36(3):159-165. doi:
10.1093/jjco/hyi234
PubMedGoogle ScholarCrossref 47.Neoptolemos
JP , Dunn
JA , Stocken
DD ,
et al; European Study Group for Pancreatic Cancer. Adjuvant chemoradiotherapy and chemotherapy in resectable pancreatic cancer: a randomised controlled trial.
Lancet. 2001;358(9293):1576-1585. doi:
10.1016/S0140-6736(01)06651-X
PubMedGoogle ScholarCrossref 48.Neoptolemos
JP , Stocken
DD , Dunn
JA ,
et al; European Study Group for Pancreatic Cancer. Influence of resection margins on survival for patients with pancreatic cancer treated by adjuvant chemoradiation and/or chemotherapy in the ESPAC-1 randomized controlled trial.
Ann Surg. 2001;234(6):758-768. doi:
10.1097/00000658-200112000-00007
PubMedGoogle ScholarCrossref 49.Neoptolemos
JP , Stocken
DD , Friess
H ,
et al; European Study Group for Pancreatic Cancer. A randomized trial of chemoradiotherapy and chemotherapy after resection of pancreatic cancer.
N Engl J Med. 2004;350(12):1200-1210. doi:
10.1056/NEJMoa032295
PubMedGoogle ScholarCrossref 50.Palmer
DH , Stocken
DD , Hewitt
H ,
et al. A randomized phase 2 trial of neoadjuvant chemotherapy in resectable pancreatic cancer: gemcitabine alone versus gemcitabine combined with cisplatin.
Ann Surg Oncol. 2007;14(7):2088-2096. doi:
10.1245/s10434-007-9384-x
PubMedGoogle ScholarCrossref 52.Abrams
RA , Winter
KA , Safran
H ,
et al. Results of the NRG Oncology/RTOG 0848 adjuvant chemotherapy question-erlotinib+gemcitabine for resected cancer of the pancreatic head: a phase II randomized clinical trial.
Am J Clin Oncol. 2020;43(3):173-179. doi:
10.1097/COC.0000000000000633
PubMedGoogle ScholarCrossref 53.Jones
RP , Psarelli
EE , Jackson
R ,
et al; European Study Group for Pancreatic Cancer. Patterns of recurrence after resection of pancreatic ductal adenocarcinoma: a secondary analysis of the ESPAC-4 randomized adjuvant chemotherapy trial.
JAMA Surg. 2019;154(11):1038-1048. doi:
10.1001/jamasurg.2019.3337
PubMedGoogle ScholarCrossref 54.Versteijne
E , Suker
M , Groothuis
K ,
et al; Dutch Pancreatic Cancer Group. Preoperative chemoradiotherapy versus immediate surgery for resectable and borderline resectable pancreatic cancer: results of the Dutch randomized phase III PREOPANC trial.
J Clin Oncol. 2020;38(16):1763-1773. doi:
10.1200/JCO.19.02274
PubMedGoogle ScholarCrossref 60.Strijker
M , van der Sijde
F , Suker
M ,
et al; Dutch Pancreatic Cancer Group. Preoperative serum ADAM12 levels as a stromal marker for overall survival and benefit of adjuvant therapy in patients with resected pancreatic and periampullary cancer.
HPB (Oxford). 2021;23(12):1886-1896. doi:
10.1016/j.hpb.2021.05.001PubMedGoogle ScholarCrossref 61.Dijk
F , Veenstra
VL , Soer
EC ,
et al. Unsupervised class discovery in pancreatic ductal adenocarcinoma reveals cell-intrinsic mesenchymal features and high concordance between existing classification systems.
Sci Rep. 2020;10(1):337. doi:
10.1038/s41598-019-56826-9
PubMedGoogle ScholarCrossref